GSK completes acquisition of efimosfermin, a potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)
07.07.25 14:00 Uhr
Werbung
GSK plc today announced the completion of its previously announced acquisition of efimosfermin alfa from Boston PharmaceuticalsWeiter zum vollständigen Artikel bei GlaxoSmithKline plc (GSK)
Quelle: EN, GlaxoSmithKline
Nachrichten zu GlaxoSmithKline PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs
Werbung
Analysen zu GlaxoSmithKline PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs
Keine Analysen gefunden.